Skip to content

Brief Behavioral Intervention for Comorbid Migraine and Depression

Brief, Behavioral Intervention of ACT & Illness Management for Comorbid Migraine and Depression

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01775852
Acronym
ACT-IM
Enrollment
45
Registered
2013-01-25
Start date
2010-08-31
Completion date
2013-08-31
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Migraine

Keywords

Acceptance and Commitment Therapy (ACT), Depression, Illness Management, Behavioral treatment, Impairment

Brief summary

The purpose of this research study is to examine whether a one-day group workshop, integrating principles from Acceptance and Commitment Therapy with Migraine Education, will result in improvements in depressive symptoms and functioning impairment in patients with comorbid migraine and depression.

Detailed description

Migraine affects approximately 35 million US residents (Bigal & Lipton, 2009) and is associated with excruciating headache and marked functional impairment. Epidemiological and clinical research has shown that people with migraine suffer from psychiatric disorders at a disproportionately higher rate than individuals without. Depression, in particular, is 3-5 times more common in migraine patients than in non-migraineurs. The comorbidity of depression and migraine is a major health concern as it results in poorer prognosis, remission rate, and response to treatment. In addition, an increase in the severity of migraine is associated with a parallel rise in the severity and treatment resistance of comorbid depression. Recent research in behavioral medicine suggests that the pain experience per se does not necessarily lead to depression or impairment. Instead, it is the preoccupation with avoiding aversive stimuli associated with pain (i.e., activities, places, movements) that results in depression and disability (e.g., McCracken et al., 2005). Therefore, given that patients with migraine and/or depression exhibit more avoidance behaviors and lower activity levels than healthy controls (e.g., Stronks et al., 2004), an intervention aimed at optimizing willingness and acceptance and minimizing behavioral avoidance may be beneficial at improving both their depression and migraine and, consequently, their daily functioning. Acceptance and Commitment Therapy (ACT) is an empirically based behavioral therapy that incorporates acceptance and mindfulness strategies with behavioral change strategies. ACT (in group and in individual settings) is effective in treating psychiatric disorders commonly associated with migraine, including depression, anxiety, and stress (e.g., Hayes, 2001) as well as chronic illnesses like pain and diabetes (Dahl et al, 2004; Gregg et al., 2006). Importantly, ACT resulted in positive long-term outcomes even when presented in brief form. For example, a two-day ACT workshop, in a group setting, led to improvements in depression and distress experienced by parents of children diagnosed with autism and these gains were retained 3 months later. Parents also exhibited a reduction in avoidance behaviors (Blackledge & Hayes, 2006).

Interventions

BEHAVIORALACT-IM

1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.

Sponsors

Lilian N. Dindo
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-75 * 4 to 12 migraines in the previous month * Major or Minor Depression * English-speaking

Exclusion criteria

* Patients with other major psychiatric disorders such as bipolor disorder, schizophrenia, and current illicit drug use. * Patients with major head injuries. * Patients with serious medical illnesses. * Patients who have started a new medication in previous 4 weeks or plan on starting a new medication in the next 4 weeks. * Patients expressing significant suicidal ideation.

Design outcomes

Primary

MeasureTime frameDescription
Mean Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 12 Week Follow-up12 week change from baselineThe HAM-D is a structured clinical interview for assessing depression severity. Outcome measure will be change from Baseline in Hamilton Depression Rating Scale at 12 week (3 month) follow-up from baseline. Measure is scored by adding individual items and attaining an overall severity score. Scores range from 0 to 53, with higher values signifying a higher level of depression severity (and thus a worse outcome). A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher (indicating at least moderate severity) is usually required for entry into a clinical trial.

Secondary

MeasureTime frameDescription
Mean Change Score in HDI (Headache Disability Inventory) From Baseline to 12 Weeks.12 week change from baselineThe HDI is useful in assessing the impact of headache, and its treatment, on daily living. 25 self-report items are rated with answers as Yes (4 points), Sometimes (2 Points), and No (0 points). All items are then added together to create an overall score which can range from 0 (no impact), to 100 (severe impact) of headache on daily life. A 29 point change (95% confidence interval) or greater in the total score from test to retest must occur before the change can be attributed to treatment effects.
Mean Change on Short Form Health Survey (SF-36) From Baseline to 12 Week Follow-up.Change at 12 week follow-up from baselineThe Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Mean Change of World Health Organization Disability Assessment (WHO-DAS) From Baseline to 12-week Follow up.Change at 12 week follow-up from baselineThe WHODAS contains 36 items on functioning and disability with a recall period of 30 days covering 7 domains: Understanding and Communicating (6 items), Getting around (5 items), Self-care (4 items), Getting along with others (5 items), Life activities: household (4 items), Life activities: work/school (4 items), and Participation in society (8 items). Response options go from 1 (no difficulty) to 5 (extreme difficulty or can not do). WHODAS domain scores are computed for each domain by adding the item responses together. A global score is then computed by summing all domains together, and transforming them into a range from 0 to 100, with higher scores indicating higher levels of disability (0= no disability, 100= full disability).

Countries

United States

Participant flow

Participants by arm

ArmCount
ACT-IM
The ACT-IM arm is a brief, one-day intervention that includes two components: 1) Illness Management for Migraine and, 2) Acceptance and Commitment Therapy for emotional difficulties that go along with, or are exacerbated by migraine. ACT-IM: 1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
31
Waitlist/Treatment as Usual
The Waitlist/Treatment as Usual (WL/TAU)condition completes the same assessments as the active treatment group but does not undergo the active treatment (workshop) until after the 12-week follow-up visit. At that point, the WL/TAU participants are given the opportunity to join a treatment workshop.
14
Total45

Baseline characteristics

CharacteristicACT-IMWaitlist/Treatment as UsualTotal
Age, Continuous32.5 years
STANDARD_DEVIATION 13.3
33.5 years
STANDARD_DEVIATION 12.9
33 years
STANDARD_DEVIATION 13.1
Sex: Female, Male
Female
30 Participants12 Participants42 Participants
Sex: Female, Male
Male
1 Participants2 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 310 / 14
serious
Total, serious adverse events
0 / 310 / 14

Outcome results

Primary

Mean Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 12 Week Follow-up

The HAM-D is a structured clinical interview for assessing depression severity. Outcome measure will be change from Baseline in Hamilton Depression Rating Scale at 12 week (3 month) follow-up from baseline. Measure is scored by adding individual items and attaining an overall severity score. Scores range from 0 to 53, with higher values signifying a higher level of depression severity (and thus a worse outcome). A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher (indicating at least moderate severity) is usually required for entry into a clinical trial.

Time frame: 12 week change from baseline

ArmMeasureValue (MEAN)Dispersion
ACT-IMMean Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 12 Week Follow-up-15.1 units on a scaleStandard Error 1.6
Waitlist/Treatment as UsualMean Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 12 Week Follow-up-4.3 units on a scaleStandard Error 2.5
Secondary

Mean Change of World Health Organization Disability Assessment (WHO-DAS) From Baseline to 12-week Follow up.

The WHODAS contains 36 items on functioning and disability with a recall period of 30 days covering 7 domains: Understanding and Communicating (6 items), Getting around (5 items), Self-care (4 items), Getting along with others (5 items), Life activities: household (4 items), Life activities: work/school (4 items), and Participation in society (8 items). Response options go from 1 (no difficulty) to 5 (extreme difficulty or can not do). WHODAS domain scores are computed for each domain by adding the item responses together. A global score is then computed by summing all domains together, and transforming them into a range from 0 to 100, with higher scores indicating higher levels of disability (0= no disability, 100= full disability).

Time frame: Change at 12 week follow-up from baseline

ArmMeasureValue (MEAN)Dispersion
ACT-IMMean Change of World Health Organization Disability Assessment (WHO-DAS) From Baseline to 12-week Follow up.-9.1 units on a scaleStandard Error 2
Waitlist/Treatment as UsualMean Change of World Health Organization Disability Assessment (WHO-DAS) From Baseline to 12-week Follow up.-.3 units on a scaleStandard Error 2.9
Secondary

Mean Change on Short Form Health Survey (SF-36) From Baseline to 12 Week Follow-up.

The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Time frame: Change at 12 week follow-up from baseline

ArmMeasureValue (MEAN)Dispersion
ACT-IMMean Change on Short Form Health Survey (SF-36) From Baseline to 12 Week Follow-up.17.0 units on a scaleStandard Error 2.5
Waitlist/Treatment as UsualMean Change on Short Form Health Survey (SF-36) From Baseline to 12 Week Follow-up.7.7 units on a scaleStandard Error 3.8
Secondary

Mean Change Score in HDI (Headache Disability Inventory) From Baseline to 12 Weeks.

The HDI is useful in assessing the impact of headache, and its treatment, on daily living. 25 self-report items are rated with answers as Yes (4 points), Sometimes (2 Points), and No (0 points). All items are then added together to create an overall score which can range from 0 (no impact), to 100 (severe impact) of headache on daily life. A 29 point change (95% confidence interval) or greater in the total score from test to retest must occur before the change can be attributed to treatment effects.

Time frame: 12 week change from baseline

ArmMeasureValue (MEAN)Dispersion
ACT-IMMean Change Score in HDI (Headache Disability Inventory) From Baseline to 12 Weeks.-27.9 units on a scaleStandard Error 3.4
Waitlist/Treatment as UsualMean Change Score in HDI (Headache Disability Inventory) From Baseline to 12 Weeks.-10.7 units on a scaleStandard Error 5.2

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026